article · Tanzania Medical Journal
A study investigated the prevalence and associated factors of Fatty Liver Disease (FLD) among people living with HIV (PLHIV) attending a care and treatment clinic in Dar es Salaam, Tanzania. Researchers conducted a cross-sectional study with 454 adult PLHIV, collecting socio-demographic, anthropometric, and clinical data, and performing abdominal ultrasounds to diagnose FLD. The findings revealed that over a quarter of the participants had FLD. Key factors significantly linked to FLD included being aged 40-60 years, being overweight or obese, and having dyslipidemia. The study concluded that FLD is common in this population and recommended targeted interventions.
Understanding the prevalence and risk factors for Fatty Liver Disease in people living with HIV is crucial for improving their long-term health outcomes. This research highlights specific groups within the HIV population who could benefit from targeted screening and preventative measures, potentially reducing the burden of chronic liver disease.
This research identifies a significant need for improved screening and intervention strategies for Fatty Liver Disease among people living with HIV, particularly those aged 40-60, overweight, obese, or with dyslipidemia. This suggests a potential for developing diagnostic tools for early detection and programmes focused on weight management and lipid control. This is early-stage research identifying a problem and risk factors, not a specific product or service.
AI-generated from the published abstract. Always read the original work before citing.
Background Fatty Liver Disease (FLD) is projected to be the leading cause of chronic liver disease among People living with HIV (PLHIV). Broad objective This study aimed at determining the magnitude and the associated factors for Fatty Liver Disease among People living with HIV attending Care and Treatment Clinic (CTC) at Temeke Regional Referral Hospital in Dar es Salaam, Tanzania. Methodology A hospital-based descriptive cross-sectional study was conducted between September and November 2020. Consenting adults aged ≥18 years and living with HIV, were enrolled in the study. A questionnaire with structured questions was used to collect socio-demographic, anthropometric measurements and clinical characteristics. Patients were fasted for a minimum of 8 hours before sonography and taking samples for lipid profile. Abdominal Ultra sonography (USS) was performed using B-mode and 3.5 MHz convex probe transducer (Dawei-DW 580, China, 2020) by a single trained investigator and confirmed by an experienced Radiologist; discrepancies were discussed by revisiting the images. FLD was defined as an increase in liver echogenicity compared to the right kidney. Independent predictors of FLD were analyzed using multivariate logistic regression; p value of < 0.05 was considered to be statistically significant. Results A total of 454 patients were enrolled into the study. FLD was visible from 118 (25.9%) (95% CI 22.0%-30.3%) patients. Factors significantly associated with FLD at multivariate analysis were; age group 40-60 years (aOR 1.74; 95% CI: 1.02 – 2.96 p=0.043), overweight (aOR 1.92; 95%CI: 1.05-3.51: p =0.034), obesity (aOR 3.46; 95% CI: 1.80 – 6.65: p < 0.001) and dyslipidemia (a OR: 2.63 95%CI: 1.58-4.39; p < 0.001). HIV viral load status and duration on combination antiretroviral therapy were not significantly associated with FLD. Conclusion and Recommendations One out of four PLHIV at Temeke Regional Referral Hospital CTC had Fatty liver Disease. Factors associated with FLD were age 40-60 years, overweight, obesity and dyslipidemia. We recommend weight reduction and regular screening for FLD among PLHIV with above risk factors.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4314/1pym3225
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
